10 studies found for:    "Leber hereditary optic neuropathy" OR "Hereditary Optic Atrophy"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
Condition: Leber Hereditary Optic Neuropathy
Intervention: Drug: rAAV2-ND4
2 Recruiting Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients
Condition: Leber Hereditary Optic Neuropathy
Intervention: Genetic: GS010
3 Completed Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy
Condition: Leber's Hereditary Optic Neuropathy
Interventions: Drug: Idebenone;   Drug: Placebo
4 Terminated Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)
Condition: Leber's Hereditary Optic Neuropathy (LHON)
Intervention: Device: Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))
5 Not yet recruiting Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey
Condition: Leber Hereditary Optic Neuropathy (LHON)
Intervention:
6 Completed RHODOS Follow-up Single-visit Study
Condition: Leber's Hereditary Optic Neuropathy
Intervention:
7 Unknown  Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)
Condition: Leber's Hereditary Optic Neuropathy
Interventions: Drug: Idebenone;   Drug: Placebo
8 Completed A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)
Condition: Optic Atrophy, Hereditary, Leber
Intervention: Drug: curcumin
9 Completed Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
Conditions: Optic Atrophy;   Non-arteritic Anterior Ischemic Optic Neuropathy
Intervention: Drug: QPI-1007 at various doses
10 Recruiting Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial Disease
Condition: Inherited Mitochondrial Disease, Including Leigh Syndrome
Intervention: Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)

Indicates status has not been verified in more than two years